Bruker Corporation | Mid-cap | Healthcare
$35.28
-1.81%
| Bruker Stock Comparison:
Bruker vs Abbott LaboratoriesBruker vs StrykerBruker vs MasimoBruker vs Globus MedicalBruker vs Bio-Rad LaboratoriesBruker vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 801.4M
Gross Profit 391.2M 48.81%
Operating Income 65.7M 8.20%
Net Income 16.8M 2.10%
EPS (Diluted) $0.11

Balance Sheet Metrics

Total Assets 5.9B
Total Liabilities 4.1B
Shareholders Equity 1.9B
Debt to Equity 2.21

Cash Flow Metrics

Operating Cash Flow 55.7M
Free Cash Flow 39.0M

Revenue & Profitability Trend

Bruker Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue i 3.4B 3.0B 2.5B 2.4B 2.0B
Cost of Goods Sold i 1.7B 1.5B 1.2B 1.2B 1.0B
Gross Profit i 1.6B 1.5B 1.3B 1.2B 939.8M
Gross Margin % i 49.0% 51.0% 51.6% 50.0% 47.3%
Operating Expenses
Research & Development i 376.5M 294.8M 235.9M 220.8M 198.0M
Selling, General & Administrative i 893.8M 730.1M 610.8M 564.5M 477.8M
Other Operating Expenses i - 5.0M 3.0M 2.8M 2.5M
Total Operating Expenses i 1.3B 1.0B 849.7M 788.1M 678.3M
Operating Income i 379.2M 488.4M 459.0M 424.3M 264.0M
Operating Margin % i 11.3% 16.5% 18.1% 17.5% 13.3%
Non-Operating Items
Interest Income i 9.3M 11.2M 4.1M 900.0K 3.2M
Interest Expense i 47.9M 16.4M 16.1M 14.3M 14.4M
Other Non-Operating Income -133.7M 61.0M -33.1M -17.3M -27.0M
Pre-tax Income i 206.9M 544.2M 413.9M 393.6M 225.8M
Income Tax i 91.4M 117.7M 116.4M 113.0M 64.4M
Effective Tax Rate % i 44.2% 21.6% 28.1% 28.7% 28.5%
Net Income i 113.8M 428.5M 298.5M 280.6M 161.4M
Net Margin % i 3.4% 14.5% 11.8% 11.6% 8.1%
Key Metrics
EBITDA i 562.6M 604.2M 548.1M 511.5M 345.1M
EPS (Basic) i $0.76 $2.92 $2.00 $1.83 $1.03
EPS (Diluted) i $0.76 $2.90 $1.99 $1.81 $1.02
Basic Shares Outstanding i 149000000 146400000 148600000 151400000 153400000
Diluted Shares Outstanding i 149000000 146400000 148600000 151400000 153400000

Income Statement Trend

Bruker Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets
Cash & Equivalents i 183.4M 488.3M 645.5M 1.1B 681.8M
Short-term Investments i - - 0 100.0M 50.0M
Accounts Receivable i 565.5M 492.0M 472.7M 416.9M 335.3M
Inventory i 1.1B 968.3M 800.1M 710.1M 692.3M
Other Current Assets 28.9M 18.3M 12.8M 172.2M 165.6M
Total Current Assets i 2.1B 2.2B 2.1B 2.5B 1.9B
Non-Current Assets
Property, Plant & Equipment i 145.5M 91.7M 51.2M 59.9M 67.4M
Goodwill i 3.9B 1.5B 1.2B 890.8M 869.9M
Intangible Assets i 912.5M 330.5M 270.9M 211.8M 229.1M
Long-term Investments - - - - -
Other Non-Current Assets 518.9M 481.2M 231.9M 160.9M 111.6M
Total Non-Current Assets i 3.8B 2.1B 1.5B 1.2B 1.1B
Total Assets i 5.8B 4.2B 3.6B 3.6B 3.0B
Liabilities
Current Liabilities
Accounts Payable i 234.1M 202.7M 178.4M 147.4M 134.6M
Short-term Debt i 64.6M 144.5M 35.1M 130.3M 23.5M
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 112.5M 34.7M 9.6M 11.6M 10.7M
Total Current Liabilities i 1.3B 1.2B 914.3M 938.5M 791.9M
Non-Current Liabilities
Long-term Debt i 2.2B 1.2B 1.2B 1.3B 889.3M
Deferred Tax Liabilities i 118.5M 67.7M 62.3M 46.0M 43.1M
Other Non-Current Liabilities 311.0M 163.6M 120.8M 162.2M 176.1M
Total Non-Current Liabilities i 2.7B 1.6B 1.6B 1.6B 1.3B
Total Liabilities i 4.0B 2.8B 2.5B 2.6B 2.1B
Equity
Common Stock i 1.8M 1.7M 1.7M 1.7M 1.7M
Retained Earnings i 2.4B 2.3B 1.9B 1.7B 1.4B
Treasury Stock i 1.2B 1.2B 1.1B 820.3M 667.0M
Other Equity - - - - -
Total Shareholders Equity i 1.8B 1.4B 1.1B 1.1B 974.3M
Key Metrics
Total Debt i 2.2B 1.4B 1.3B 1.4B 912.8M
Working Capital i 771.9M 962.1M 1.2B 1.5B 1.1B

Balance Sheet Composition

Bruker Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income i 113.8M 428.5M 298.5M 280.6M 161.4M
Depreciation & Amortization i 183.8M 114.9M 88.8M 89.1M 80.4M
Stock-Based Compensation i 25.3M 24.0M 27.7M 17.2M 16.0M
Working Capital Changes i -62.9M -131.5M -137.3M -81.3M 26.7M
Operating Cash Flow i 233.5M 292.7M 289.7M 327.8M 289.3M
Investing Activities
Capital Expenditures i -114.2M -95.8M -115.3M -87.1M -97.0M
Acquisitions i -1.6B -226.6M -182.3M -65.0M -59.2M
Investment Purchases i -48.3M -24.8M -60.2M -148.5M -151.2M
Investment Sales i 4.8M 21.2M 106.2M 108.2M 114.7M
Investing Cash Flow i -1.8B -326.0M -251.6M -192.4M -192.7M
Financing Activities
Share Repurchases i 0 -152.3M -263.1M -153.3M -123.2M
Dividends Paid i -30.2M -29.4M -29.8M -24.2M -24.6M
Debt Issuance i 2.2B - 300.0K 490.5M 0
Debt Repayment i -1.3B -21.5M -111.0M -800.0K -305.8M
Financing Cash Flow i 1.2B -193.4M -415.3M 318.7M -466.7M
Free Cash Flow i 136.0M 243.2M 145.2M 190.4M 235.0M
Net Change in Cash i -300.0M -226.7M -377.2M 454.1M -370.1M

Cash Flow Trend

Bruker Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 66.46
Forward P/E 12.75
Price to Book 2.91
Price to Sales 1.52
PEG Ratio 12.75

Profitability Ratios

Profit Margin 2.31%
Operating Margin 3.61%
Return on Equity 4.07%
Return on Assets 3.55%

Financial Health

Current Ratio 1.60
Debt to Equity 132.75
Beta 1.20

Per Share Data

EPS (TTM) $0.52
Book Value per Share $11.89
Revenue per Share $22.70

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
brkr 5.2B 66.46 2.91 4.07% 2.31% 132.75
Abbott Laboratories 230.7B 16.73 4.59 30.93% 32.43% 26.50
Stryker 143.5B 49.84 6.77 14.25% 12.25% 80.83
Masimo 8.4B 129.16 7.83 -22.37% -21.32% 61.58
Globus Medical 8.3B 23.35 1.86 8.62% 13.58% 2.83
Bio-Rad Laboratories 8.3B 27.11 1.14 4.59% 12.50% 19.73

Financial data is updated regularly. All figures are in the company's reporting currency.